These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 25669425)
1. Surveillance of probably benign (BI-RADS 3) lesions in mammography: what is the right follow-up protocol? Buch KA; Qureshi MM; Carpentier B; Cunningham DA; Stone M; Jaffe C; Quinn M; Gonzalez C; LaVoye J; Hines N; Bloch BN Breast J; 2015; 21(2):168-74. PubMed ID: 25669425 [TBL] [Abstract][Full Text] [Related]
2. Revisiting the mammographic follow-up of BI-RADS category 3 lesions. Varas X; Leborgne JH; Leborgne F; Mezzera J; Jaumandreu S; Leborgne F AJR Am J Roentgenol; 2002 Sep; 179(3):691-5. PubMed ID: 12185047 [TBL] [Abstract][Full Text] [Related]
3. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions. Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725 [TBL] [Abstract][Full Text] [Related]
4. Reassessment and Follow-Up Results of BI-RADS Category 3 Lesions Detected on Screening Breast Ultrasound. Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH AJR Am J Roentgenol; 2016 Mar; 206(3):666-72. PubMed ID: 26901026 [TBL] [Abstract][Full Text] [Related]
5. Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance. Michaels A; Chung CS; Birdwell RL; Frost EP; Giess CS Breast J; 2017 Jan; 23(1):10-16. PubMed ID: 27612001 [TBL] [Abstract][Full Text] [Related]
6. Linked claims and medical records for cancer case management : evaluation of mammography abnormalities. Eberl MM; Watroba N; Reinhardt M; Pomerantz J; Serghany J; Broffman G; Fox CH; Mahoney MC; Edge SB Cancer; 2007 Aug; 110(3):518-24. PubMed ID: 17577210 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. Mendez A; Cabanillas F; Echenique M; Malekshamran K; Perez I; Ramos E Cancer; 2004 Feb; 100(4):710-4. PubMed ID: 14770425 [TBL] [Abstract][Full Text] [Related]
8. Computer-aided classification of BI-RADS category 3 breast lesions. Buchbinder SS; Leichter IS; Lederman RB; Novak B; Bamberger PN; Sklair-Levy M; Yarmish G; Fields SI Radiology; 2004 Mar; 230(3):820-3. PubMed ID: 14739315 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the results after using of the BI-RADS categories in 1,777 clinical mammograms]. Hauth EA; Khan K; Wolfgarten B; Betzler A; Kimmig R; Forsting M Radiologe; 2008 Mar; 48(3):281-8. PubMed ID: 17265008 [TBL] [Abstract][Full Text] [Related]
10. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database. Berg WA; Berg JM; Sickles EA; Burnside ES; Zuley ML; Rosenberg RD; Lee CS Radiology; 2020 Jul; 296(1):32-41. PubMed ID: 32427557 [TBL] [Abstract][Full Text] [Related]
11. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology]. Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279 [TBL] [Abstract][Full Text] [Related]
12. Tomosynthesis in the Diagnostic Setting: Changing Rates of BI-RADS Final Assessment over Time. Raghu M; Durand MA; Andrejeva L; Goehler A; Michalski MH; Geisel JL; Hooley RJ; Horvath LJ; Butler R; Forman HP; Philpotts LE Radiology; 2016 Oct; 281(1):54-61. PubMed ID: 27139264 [TBL] [Abstract][Full Text] [Related]
13. MR imaging in probably benign lesions (BI-RADS category 3) of the breast. Gökalp G; Topal U Eur J Radiol; 2006 Mar; 57(3):436-44. PubMed ID: 16316732 [TBL] [Abstract][Full Text] [Related]
14. [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]. Lorenzen J; Wedel AK; Lisboa BW; Löning T; Adam G Rofo; 2005 Nov; 177(11):1545-51. PubMed ID: 16302136 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of unconventional utilization of BI-RADS category 3 assessment at opportunistic screening. Altas H; Tureli D; Cengic I; Kucukkaya F; Aribal E; Kaya H Acta Radiol; 2016 Nov; 57(11):1304-1309. PubMed ID: 26019241 [TBL] [Abstract][Full Text] [Related]
16. BI-RADS categorization as a predictor of malignancy. Orel SG; Kay N; Reynolds C; Sullivan DC Radiology; 1999 Jun; 211(3):845-50. PubMed ID: 10352614 [TBL] [Abstract][Full Text] [Related]
17. Comparison of rate of development and rate of change for benign and malignant breast calcifications at the lumpectomy bed. Giess CS; Keating DM; Osborne MP; Mester J; Rosenblatt R AJR Am J Roentgenol; 2000 Sep; 175(3):789-93. PubMed ID: 10954468 [TBL] [Abstract][Full Text] [Related]
18. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions? Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693 [TBL] [Abstract][Full Text] [Related]
19. BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome. Raza S; Chikarmane SA; Neilsen SS; Zorn LM; Birdwell RL Radiology; 2008 Sep; 248(3):773-81. PubMed ID: 18647850 [TBL] [Abstract][Full Text] [Related]
20. Does training in the Breast Imaging Reporting and Data System (BI-RADS) improve biopsy recommendations or feature analysis agreement with experienced breast imagers at mammography? Berg WA; D'Orsi CJ; Jackson VP; Bassett LW; Beam CA; Lewis RS; Crewson PE Radiology; 2002 Sep; 224(3):871-80. PubMed ID: 12202727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]